SOTIO to Present Preclinical Results Describing SOT102 as Treatment of Solid Tumors at the American Association of Cancer Research Annual Meeting

April 6, 2021
Source: Press Release

SOTIO, a clinical stage immuno-oncology company owned by PPF Group, today announced the presentation of a virtual poster at the 2021 American Association of Cancer Research Annual Meeting. The presentation focuses on preclinical data describing SOT102 which is intended for the treatment of CLDN18.2-expressing solid tumors.

SOT102 (earlier SO-N102) is a CLDN18.2 targeting antibody-drug conjugate based on a novel proprietary, highly-specific monoclonal antibody conjugated to a potent cytotoxic drug molecule exhibiting strong anti-tumor activity. SOT102 was studied in models of various CLDN18.2-positive solid tumors, mainly of gastric and pancreatic origin. 

Poster Presentation details: 
Title: SOT102, a novel CLDN18.2-targeting antibody-drug conjugate with strong anti-tumor effect in various solid tumors expressing low target levels
Poster Number: 1204
Session: PO.ET01.05 - New Targets
Presenting Author: Lenka Kyrych Sadilkova, Ph.D. 
Date/ Time: Saturday, April 10, 2021 from 8:30 AM - 11:59 PM EST 
Conference Registration Link:

A copy of the presentation materials can be accessed on the SOTIO website once the presentation concludes.